Please login to the form below

Not currently logged in
Email:
Password:

Endocyte appoints Parexel's Scot Harper to oversee clinical trials

He also previously served at Novartis and Lilly

Scot Harper, Endocyte Endocyte has appointed Dr Scot Harper as VP, clinical operations, where he will be responsible for clinical trial operations at the US biopharma company.

Dr Harper (pictured right) joins from clinical research organisation (CRO) Parexel, where he held the role of global portfolio director for oncology, overseeing clinical activities for cancer drugs from phase I to IV development.

He also has experience working in clinical operations for major pharma companies, serving as VP of Novartis' North American clinical operations, and senior director of clinical operations at Lilly.

Prior to this, Dr Harper worked in new product development at SmithKline Beechham.

Endocyte, which focuses on developing therapies for the treatment of cancer and other serious diseases, will benefit from his experience of working on the development of major oncology brands like Tasigna and Gleevec.

“Scot has deep expertise in the drug development process and management of all stages of clinical trials, and he will play a key role at Endocyte as we seek to expand and advance our platform,” said Ron Ellis, Endocyte's president and CEO, referencing the development of oncology candidates vintafolide and etarfolatide, which are in phase III and phase II trials respectively.

In addition, Endocyte says it has three new drug candidates scheduled to enter the clinic before the end of 2014.

9th May 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...